CA2541599C - Blister pack and solid dosage form therefor - Google Patents

Blister pack and solid dosage form therefor Download PDF

Info

Publication number: CA2541599C
Authority: CA; Canada
Prior art keywords: dosage form; solid dosage; blister pack; acid; desmopressin
Prior art date: 2003-11-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2541599A

Other languages

English (en)

French (fr)

Other versions

CA2541599A1 (en

Inventor

Kristin Wannerberger

Lars Anders Ragnar Nilsson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ferring BV

Original Assignee

Ferring BV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-13

Filing date

2004-11-12

Publication date

2011-01-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34429342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2541599(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-11-12 Application filed by Ferring BV filed Critical Ferring BV

2005-05-26 Publication of CA2541599A1 publication Critical patent/CA2541599A1/en

2011-01-25 Application granted granted Critical

2011-01-25 Publication of CA2541599C publication Critical patent/CA2541599C/en

2024-11-12 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000007909 solid dosage form Substances 0.000 title claims abstract description 47
108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims abstract description 31
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims abstract description 27
229960004281 desmopressin Drugs 0.000 claims abstract description 26
150000003839 salts Chemical class 0.000 claims abstract description 7
230000015556 catabolic process Effects 0.000 claims abstract description 6
238000006731 degradation reaction Methods 0.000 claims abstract description 6
239000002671 adjuvant Substances 0.000 claims abstract description 5
239000003085 diluting agent Substances 0.000 claims abstract description 5
239000003826 tablet Substances 0.000 claims description 33
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 15
239000003795 chemical substances by application Substances 0.000 claims description 12
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 12
229920001328 Polyvinylidene chloride Polymers 0.000 claims description 9
239000005033 polyvinylidene chloride Substances 0.000 claims description 9
239000004743 Polypropylene Substances 0.000 claims description 8
239000008187 granular material Substances 0.000 claims description 8
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 7
239000004713 Cyclic olefin copolymer Substances 0.000 claims description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 7
239000001630 malic acid Substances 0.000 claims description 7
235000011090 malic acid Nutrition 0.000 claims description 7
239000005030 aluminium foil Substances 0.000 claims description 6
239000000463 material Substances 0.000 claims description 6
239000000843 powder Substances 0.000 claims description 6
239000002702 enteric coating Substances 0.000 claims description 5
238000009505 enteric coating Methods 0.000 claims description 5
239000004952 Polyamide Substances 0.000 claims description 4
239000004698 Polyethylene Substances 0.000 claims description 4
235000015165 citric acid Nutrition 0.000 claims description 4
229920002647 polyamide Polymers 0.000 claims description 4
-1 polyes-ter Substances 0.000 claims description 4
239000005020 polyethylene terephthalate Substances 0.000 claims description 4
239000004793 Polystyrene Substances 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 3
239000007937 lozenge Substances 0.000 claims description 3
239000000123 paper Substances 0.000 claims description 3
229920000728 polyester Polymers 0.000 claims description 3
229920002223 polystyrene Polymers 0.000 claims description 3
241000251468 Actinopterygii Species 0.000 claims description 2
108010010803 Gelatin Proteins 0.000 claims description 2
229920000159 gelatin Polymers 0.000 claims description 2
239000008273 gelatin Substances 0.000 claims description 2
235000019322 gelatine Nutrition 0.000 claims description 2
235000011852 gelatine desserts Nutrition 0.000 claims description 2
235000011167 hydrochloric acid Nutrition 0.000 claims 2
229960000443 hydrochloric acid Drugs 0.000 claims 2
239000011248 coating agent Substances 0.000 claims 1
238000000576 coating method Methods 0.000 claims 1
239000004800 polyvinyl chloride Substances 0.000 description 14
MLSVJHOYXJGGTR-IFHOVBQLSA-N acetic acid;(2s)-n-[(2r)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4r,7s,10s,13s,16s)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,1 Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 MLSVJHOYXJGGTR-IFHOVBQLSA-N 0.000 description 13
229920000915 polyvinyl chloride Polymers 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
239000004411 aluminium Substances 0.000 description 6
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
229910052782 aluminium Inorganic materials 0.000 description 6
239000011888 foil Substances 0.000 description 6
238000003860 storage Methods 0.000 description 6
229920000089 Cyclic olefin copolymer Polymers 0.000 description 5
239000002002 slurry Substances 0.000 description 5
238000005469 granulation Methods 0.000 description 4
230000003179 granulation Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229940028441 minirin Drugs 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
229920001592 potato starch Polymers 0.000 description 3
238000007789 sealing Methods 0.000 description 3
FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000654 additive Substances 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
239000002131 composite material Substances 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
229960002845 desmopressin acetate Drugs 0.000 description 2
238000001035 drying Methods 0.000 description 2
239000004920 heat-sealing lacquer Substances 0.000 description 2
239000004922 lacquer Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
238000007873 sieving Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000008967 Enuresis Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
159000000021 acetate salts Chemical class 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000013475 authorization Methods 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
201000010064 diabetes insipidus Diseases 0.000 description 1
239000000539 dimer Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000004941 influx Effects 0.000 description 1
238000003475 lamination Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000000034 method Methods 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
206010029446 nocturia Diseases 0.000 description 1
208000005346 nocturnal enuresis Diseases 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
238000001139 pH measurement Methods 0.000 description 1
238000012536 packaging technology Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000013112 stability test Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Packages (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA2541599A 2003-11-13 2004-11-12 Blister pack and solid dosage form therefor Expired - Fee Related CA2541599C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP03025959.2		2003-11-13
EP03025959A EP1530967B1 (de)	2003-11-13	2003-11-13	Blisterverpackung und feste Dosierungsform enthaltend Desmopressin
PCT/EP2004/052940 WO2005046646A2 (en)	2003-11-13	2004-11-12	Blister pack and solid dosage form comprising desmopressin

Publications (2)

Publication Number	Publication Date
CA2541599A1 CA2541599A1 (en)	2005-05-26
CA2541599C true CA2541599C (en)	2011-01-25

Family

ID=34429342

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2541599A Expired - Fee Related CA2541599C (en)	2003-11-13	2004-11-12	Blister pack and solid dosage form therefor

Country Status (10)

Country	Link
US (1)	US8119161B2 (de)
EP (1)	EP1530967B1 (de)
JP (1)	JP5180477B2 (de)
AT (1)	ATE324869T1 (de)
CA (1)	CA2541599C (de)
DE (1)	DE60305043T2 (de)
DK (1)	DK1530967T3 (de)
ES (1)	ES2260563T3 (de)
PT (1)	PT1530967E (de)
WO (1)	WO2005046646A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0210397D0 (en)	2002-05-07	2002-06-12	Ferring Bv	Pharmaceutical formulations
ES2260563T3 (es)	2003-11-13	2006-11-01	Ferring B.V.	Paquete de blister y forma farmaceutica solida para ello.
SE528446C2 (sv) *	2006-03-02	2006-11-14	Ferring Int Ct Sa	Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
CA2584456C (en) *	2006-03-02	2008-07-22	Ferring International Center S.A.	Composition comprising desmopressin
US20110005961A1 (en) *	2008-02-28	2011-01-13	Ludovic Leplatois	Extrusion-Coated Lidding Foil For Push-Through Blister Packaging
SI2712622T1 (sl)	2008-05-21	2016-10-28	Ferring B.V.	Orodisperzibilni dezmopresin za povečanje začetnega obdobja spanja nemotenega z nokturijo
US11963995B2 (en)	2008-05-21	2024-04-23	Ferring B.V.	Methods comprising desmopressin
US20100286045A1 (en)	2008-05-21	2010-11-11	Bjarke Mirner Klein	Methods comprising desmopressin

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1548022A (en)	1976-10-06	1979-07-04	Wyeth John & Brother Ltd	Pharmaceutial dosage forms
US4285858A (en)	1979-10-30	1981-08-25	Mt. Sinai School Of Medicine Of The City University Of N.Y.	Vasopressin analogs
US4263283A (en)	1980-05-16	1981-04-21	Ferring Pharmaceuticals, Inc.	Method for prophylaxis and/or treatment of sickle cell disease
GB2111423B (en)	1981-12-02	1985-06-26	Wyeth John & Brother Ltd	Making quick-dissolving pills
DE3264450D1 (en)	1981-12-11	1985-08-01	Wyeth John & Brother Ltd	Process and apparatus for freezing a liquid medium
ATE24964T1 (de)	1981-12-11	1987-01-15	Wyeth John & Brother Ltd	Verfahren zur herstellung von festen formgegenstaenden.
SE8306367L (sv) *	1983-11-18	1985-05-19	Ferring Ab	Antidiuretiskt verkande farmaceutiskt preparat
US4863737A (en)	1985-05-01	1989-09-05	University Of Utah	Compositions and methods of manufacture of compressed powder medicaments
US4731360A (en)	1985-08-16	1988-03-15	Merck & Co., Inc.	Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4764378A (en)	1986-02-10	1988-08-16	Zetachron, Inc.	Buccal drug dosage form
US6746678B1 (en)	1991-02-22	2004-06-08	Howard K. Shapiro	Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
CA2070061C (en)	1991-06-07	2004-02-10	Shigeyuki Takama	Physiologically active polypeptide-containing pharmaceutical composition
ATE172637T1 (de) *	1991-12-24	1998-11-15	Yamanouchi Pharma Co Ltd	Intrabukkal desintegrierende zubereitung und ihre herstellung
US5298256A (en) *	1992-04-28	1994-03-29	Corint, Ltd.	Desmopressin buccal patch composition
US5343672A (en)	1992-12-01	1994-09-06	Scherer Ltd R P	Method for manufacturing freeze dried dosages in a multilaminate blister pack
SE9300937L (sv)	1993-03-19	1994-09-20	Anne Fjellestad Paulsen	Komposition för oral administrering av peptider
SE501677C2 (sv)	1993-06-18	1995-04-10	Ferring Bv	Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel
US5482931A (en)	1993-06-29	1996-01-09	Ferring Ab	Stabilized pharmaceutical peptide compositions
US5500413A (en)	1993-06-29	1996-03-19	Ferring Ab	Process for manufacture of 1-deamino-8-D-arginine vasopressin
WO1995001368A1 (en)	1993-06-29	1995-01-12	Ferring B.V.	Improved synthesis of cyclic peptides
US5674850A (en)	1993-12-23	1997-10-07	Ferring Ab	High purity desmopressin produced in large single batches
US5985835A (en)	1993-12-23	1999-11-16	Ferring B.V.	Desmopressin for nocturia, incontinence and enuresis
RU2135204C1 (ru)	1993-06-29	1999-08-27	Ферринг Б.В.	Составы для назального введения десмопрессина
SE9400918L (sv) *	1994-03-18	1995-09-19	Anne Fjellstad Paulsen	Stabiliserad komposition för oral administrering av peptider
US5849322A (en)	1995-10-23	1998-12-15	Theratech, Inc.	Compositions and methods for buccal delivery of pharmaceutical agents
US5763398A (en)	1996-06-20	1998-06-09	Ferring B.V.	Nasal administration of desmopressin
US5922680A (en)	1996-10-23	1999-07-13	Ferring, B.V.	Stabilized composition for oral administration of peptides
SE9604341D0 (sv)	1996-11-26	1996-11-26	Ferring Bv	Hepta-peptide oxytocin analogue
US5976577A (en)	1997-07-11	1999-11-02	Rp Scherer Corporation	Process for preparing fast dispersing solid oral dosage form
GB9827292D0 (en)	1998-12-12	1999-02-03	Univ Strathclyde	Freeze drying
US20060025387A1 (en)	1998-12-23	2006-02-02	Cytoscan Sciences Llc	Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
GB9901819D0 (en)	1999-01-27	1999-03-17	Scherer Corp R P	Pharmaceutical compositions
KR20100008007A (ko)	1999-02-15	2010-01-22	다이닛본 스미토모 세이야꾸 가부시끼가이샤	구강내에서 신속하게 붕괴되는 정제
AR014640A1 (es)	1999-02-23	2001-03-28	Univ Nac Quilmes	UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE.
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7060708B2 (en)	1999-03-10	2006-06-13	New River Pharmaceuticals Inc.	Active agent delivery systems and methods for protecting and administering active agents
US6210699B1 (en)	1999-04-01	2001-04-03	Watson Pharmaceuticals, Inc.	Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
GB9908014D0 (en)	1999-04-08	1999-06-02	Scherer Corp R P	Pharmaceutical compositions
GB2355454A (en)	1999-10-20	2001-04-25	Ferring Bv	Antidiuretic agents
US6264981B1 (en)	1999-10-27	2001-07-24	Anesta Corporation	Oral transmucosal drug dosage using solid solution
GB0000079D0 (en)	2000-01-05	2000-02-23	Ferring Bv	Novel antidiuretic agents
AT409081B (de) *	2000-02-16	2002-05-27	Gebro Pharma Gmbh	Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
GB0015601D0 (en)	2000-06-26	2000-08-16	Ferring Bv	Novel antidiuretic agents
TWI287984B (en)	2000-10-17	2007-10-11	Wyeth Corp	Pharmaceutical composition for modulating bladder function
DE02715112T1 (de)	2001-03-16	2007-04-19	Alza Corp., Mountain View	Transdermales pflaster zur verabreichung von fentanyl
US6509040B1 (en)	2001-06-22	2003-01-21	R.P. Scherer Corporation	Fast dispersing dosage forms essentially free of mammalian gelatin
GB0210397D0 (en)	2002-05-07	2002-06-12	Ferring Bv	Pharmaceutical formulations
PT1501534E (pt) *	2002-05-07	2006-09-29	Ferring Bv	Formulacoes farmaceuticas
US20060193825A1 (en)	2003-04-29	2006-08-31	Praecis Phamaceuticals, Inc.	Pharmaceutical formulations for sustained drug delivery
US7094545B2 (en)	2003-04-30	2006-08-22	Ferring Bv	Pharmaceutical composition as solid dosage form and method for manufacturing thereof
ATE301990T1 (de)	2003-07-25	2005-09-15	Ferring Bv	Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung
CN1826099B (zh)	2003-07-25	2010-06-09	凡林有限公司	固体剂型药物组合物及其制造方法
CA2866501A1 (en)	2003-11-10	2005-05-26	Allergan, Inc.	Pharmaceutical compositions including low dosages of desmopressin
ES2260563T3 (es)	2003-11-13	2006-11-01	Ferring B.V.	Paquete de blister y forma farmaceutica solida para ello.
US7018653B2 (en)	2003-12-29	2006-03-28	Ferring B.V.	Method for preparing solid dosage form of desmopressin
US7295874B2 (en) *	2005-01-06	2007-11-13	Cardiac Pacemakers, Inc.	Intermittent stress augmentation pacing for cardioprotective effect
RU2007139543A (ru)	2005-04-22	2009-05-27	Вайет (Us)	Производные бензодиоксана и бензодиоксолана и их применение
SE528446C2 (sv)	2006-03-02	2006-11-14	Ferring Int Ct Sa	Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse

2003
- 2003-11-13 ES ES03025959T patent/ES2260563T3/es not_active Expired - Lifetime
- 2003-11-13 PT PT03025959T patent/PT1530967E/pt unknown
- 2003-11-13 EP EP03025959A patent/EP1530967B1/de not_active Expired - Lifetime
- 2003-11-13 DK DK03025959T patent/DK1530967T3/da active
- 2003-11-13 AT AT03025959T patent/ATE324869T1/de active
- 2003-11-13 DE DE60305043T patent/DE60305043T2/de not_active Expired - Lifetime
2004
- 2004-11-12 US US10/519,715 patent/US8119161B2/en not_active Expired - Lifetime
- 2004-11-12 CA CA2541599A patent/CA2541599C/en not_active Expired - Fee Related
- 2004-11-12 JP JP2006538867A patent/JP5180477B2/ja not_active Expired - Lifetime
- 2004-11-12 WO PCT/EP2004/052940 patent/WO2005046646A2/en not_active Ceased

Also Published As

Publication number	Publication date
HK1078268A1 (en)	2006-03-10
US20070117759A1 (en)	2007-05-24
US8119161B2 (en)	2012-02-21
DK1530967T3 (da)	2006-07-03
PT1530967E (pt)	2006-09-29
ATE324869T1 (de)	2006-06-15
WO2005046646A2 (en)	2005-05-26
EP1530967B1 (de)	2006-05-03
EP1530967A1 (de)	2005-05-18
DE60305043T2 (de)	2006-11-30
WO2005046646A3 (en)	2007-02-22
JP5180477B2 (ja)	2013-04-10
JP2007521327A (ja)	2007-08-02
CA2541599A1 (en)	2005-05-26
DE60305043D1 (de)	2006-06-08
ES2260563T3 (es)	2006-11-01

Legal Events

Date	Code	Title	Description
2006-04-05	EEER	Examination request
2014-12-24	MKLA	Lapsed	Effective date: 20141112

Publication	Publication Date	Title
KR102240429B1 (ko)	2021-04-15	로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
US20050220865A1 (en)	2005-10-06	Compressed composition comprising magnesium salt
JP6283316B2 (ja)	2018-02-21	アナグリプチン含有固形製剤
JP7074231B2 (ja)	2022-05-24	固形製剤
US8119161B2 (en)	2012-02-21	Blister pack and solid dosage form therefor
JP2019011327A (ja)	2019-01-24	医薬組成物
US20050169981A1 (en)	2005-08-04	Solid compositions comprising ramipril
US20110112160A1 (en)	2011-05-12	Tablet comprising eprosartan mesylate
US7018653B2 (en)	2006-03-28	Method for preparing solid dosage form of desmopressin
WO2008132756A1 (en)	2008-11-06	Stable pharmaceutical compositions of ramipril
US20100035955A1 (en)	2010-02-11	Stabilised Composition Comprising ACE Inhibitors
HK1078268B (en)	2006-07-14	Blister pack and solid dosage form comprising desmopressin
JPH02286614A (ja)	1990-11-26	アセトアミノフェン製剤
EP1550439A1 (de)	2005-07-06	Verfahren zur Herstellung einer festen oralen Dosierungsform von Desmopressin
WO2008001184A2 (en)	2008-01-03	Solid composition
SK50252005A3 (sk)	2006-10-05	Farmaceutický prípravok obsahujúci perindopril erbumín, spôsob jeho prípravy a stabilizácie
JP2025070801A (ja)	2025-05-02	医薬組成物および包装医薬品
RU2334505C2 (ru)	2008-09-27	Способ приготовления твердой лекарственной формы десмопрессина
JP2024171243A (ja)	2024-12-11	フィルムコーティング錠
HUP0001823A2 (hu)	2001-04-28	Kémiailag állandó és hőstabil norastemizol készítmények
JP2004073377A (ja)	2004-03-11	固形医薬組成物中の有効成分の安定化方法
EA045037B1 (ru)	2023-10-26	Фармацевтические составы ингибиторов индоламин-2,3-диоксигеназы
JP2004075582A (ja)	2004-03-11	固形医薬組成物に処方される有効成分以外の成分の安定化方法
US20060134193A1 (en)	2006-06-22	Method to improve pharmaceutical tablets having a matrix of cellulose ether
AU2002325125A1 (en)	2003-04-14	Solid compositions comprising ramipril